- QPA 2025-39 Service users ordering household items to self harm (Sodium Nitrite and Epsom Salts)
- QPA 2025-38 GlucoRx HCT External Quality Assurance
- QPA 2025-37 Reporting Catheter Associated Urinary Tract Infection (CAUTI)
- QPA 2025-36 Rapid Tranquillisation POMH audit results and update to the Trust-wide procedure
- QPA 2025-35 Managing pain in Community Nursing
- QPA 2025-34 Environmental Suicide Risk – Ligature Point from Anti-Barricade Doors
- QPA 2025-33 Risk of Propranolol Use
- QPA 2025-32 Documents containing Information on Medicines
- QPA 2025-31 Access to Mounjaro (Tirzepatide) and Wegovy (Semaglutide) for weight loss
- QPA 2025-30 Secruity Alert Scissors Disguised as a pen
- QPA 2025-29 Covid - 19 Treatment Guidlines
- QPA 2025-28 Primera lock override and re-set requirement
- QPA 2025-27 Medicines Information Resources
- QPA 2025-26 Steroid Medication Review, Supply and Emergency Card to Support Early Recognition and Treatment of Adrenal Crisis in Adults and prevent inappropriate long-term use
- QPA 2025-25 Recording of historical risk/ harm/ suicide attempts that present for initial assessment withing the Talking Therapies service
- QPA 2025-24 Procedure for the Use of Access to Trust-wide Activity of Daily Living (ADL)/ Theraputic kitchens
- QPA 2025-23 Atypical Antipsychotics GP prescribing and discharge letters
- QPA 2025-22 Fire Safety risk with V3 Safety Pods
- QPA 2025-21 Recall of Invalid/ Out of Date FP10 Prescription Pads
- QPA 2025-20 Dealing with Temperature Excursions
- QPA 2025-19 Visitors Book - Signing in books
- QPA 2025-18 Updates to MMP23 Safe Use of Valproate Procedure
- QPA 2025-17 Amputation risk stratification - incident review process
- QPA 2025-16 (v2) Obtaining inpatient medicines outside normal pharmacy working hours (9am to 5pm, Monday to Friday)
- QPA 2025-15 New Chief Coroners Guidance for Coroners on the Bench
- QPA 2025-14 Change to the Ordering and Supply of Non-Drug Items (effective immediately)
- QPA 2025-13 Safe administration of insullin in community settings
- QPA 2025-12 Patient Identification - Medicines Administration
- QPA 2025-11 Changes to MAC and MAP reports with discontinued medication
- QPA 2025-10 Changes to medication times on the new harmonised and upgraded EPMA sytem
- QPA 2025-09 Changes to alerts with dicontinued medications and discharge prescriptions on the new harmonised EPMA system
- QPA 2025-08 Relating to the Management and Recognition of the Deteriorating Patietn - NEW2 (National Early Warning Score RCP 2019) within the Community Care Division
- QPA 2025-07 Introduction of New Safety Measures with Topiramate
- QPA 2025-06 The use of What3Words for determining the location of service users in clinical settings
- QPA 2025-05 Care of balloon gastrostomy enteral feeding tubes
- QPA 2025-04 Rapid Tranquilisation Polcy and Procedures (updated)
- QPA 2025-03 Environmental Risk - Ligature point from Window Frames
- QPA 2025-02 Rapid Tranquillisation Policy and Procedures (updated)
- QPA 2025-01 Guidance on the completion of MFRAT and Falls Person-Centreed Care Plans for Inpatients on RiO
- QPA 2024-62 Appropriate prescribing of oral nutritional suppolements in the community setting
- QPA 2024-61 High Dose Antipsychotic Therapy (HDAT) Risk Assessment Form
- QPA 2024-60 Prohibited Item: Lighters in Inpatient Areas
- QPA 2024-59 Importance of supportive and physical observationsQPA 2024-58 Update to Depsis Guidance and NEWS2 escalation
- QPA 2024-57 Folic Acid supplemention - Continued for those who are planning a pregnancy or are newly pregnant.
- QPA 2024-56 Ensuite Collapsible Door Yewdale Safedoor 1
- QPA 2024-55 Clinical Records Standards
- QPA 2024-54 Getting medicines formulary shared care documentation right GP Collective Action Impact
- QPA 2024-53 Ensuring fire rating of bedding items in the ward environment
- QPA 2024-52 Summary Case Record Obtaining relevant Patient Status and Past Medical History on Admission
- QPA 2024-51 Patient Infromation leaflet (PIL) for Paracetamol Effervescent Tablets produced by Kent Phama UK
- QPA 2024-50 Safe Management of Sharps bins within healthcare workers vehicles
- QPA 2024-49 Safe storage and disposal of Pharmaceutical waste (excluding Controlled drugs)
- QPA 2024-48 EPMA - Prescribing and administering when required (PRN) medication
- QPA 2024-47 Accumulated Anticholinergic Burden
- QPA 2024-46 Environmental Ligature Points (Windows and Door Frames)
- 7 Minute Briefing- Depots - Sep 2024
- QPA 2024-45 Contamination of mustard with peanuts for patients with peanut allergy
- QPA 2024-44 In the event of a Patient Death within the Secure Care Division
- QPA 2024-43 Introduction of Medical Examiners and changes to the death certification process
- QPA 2024-42 Device Flipper Zero which can replicate remotes bank cards car keys and access control mechanisms
- QPA 2024-41 The use of Biozoon Air with flavour device
- QPA 2024-40 Risk of falls from hospital windows and maintenance of window restrictor
- QPA 2024-39 Appropriate management of Social Media when presenting at a Mersey Care site
- QPA 2024-38 Planned admissions for Service Users with mobility and/ or additional physical health needs
- QPA 2024-37 Controlled Drug Hanover Risk Assessment (CCD Only)
- QPA 2024-36 Dealing with Temperature Excursions
- QPA 2024-35 Transcribing of Medication - Inpatient GP Discharge Summary
- QPA 2024-34 COVID RIDDOR Reporting
- QPA 2024-33 Data Quality Standards for recording clinical incidents on the Patients Clinical Heatlh Record (RIO, PACIS & EMIS) and Trust Incident Reporting System (RADAR)
- QPA 2024-06 Nursing Reviews of Secluded Patients (Updated July 2024)
- QPA 2024-32 Recording Rio alerts for service users who experience seizures to support with personalised care planning
- QPA 2024-31 Updates to the Safe Management of Controlled Drugs on Inpatient Wards v2 (Updated July 2024)
- QPA 2024-30 Designated location of Nursing Care Plans on service user's electronic record (PCIS/ RIO)
- QPA 2024-29 Annual health Checks for people with learning disability (Age 14+) 17.6.24
- QPA- 2024-28 Staff Guidance on Quetiapine shortage 12.6.24
- QPA 2024-27 Staff Guidance on Use of Personal Mobile Phones in Inpatient Settings and Urgent Care 6.6.24
- QPA 2024-26 Cleaning Display Screen for Welch Allyn Connnex Vital Signs Monitors 3.6.24
- QPA 2024-25 Battery Management & Recharging Batteries for Welch Allyn Vial Signs Monitors 3.6.24
- QPA 2024-24 Update for the Battery management of Bodyguard T Ambulatory Syringe Drivers 3.6.24
- QPA 2024-23 Update for Standardisation of the Date of all Bodyguard T Ambulatory Syringe Drivers 3.6.24
- QPA 2024-22 Safe use of Valproate medicines - Pathways and Intranet page 28.5.24
- QPA 2024-21 Identification of service users prescribed Clozapine on MAST using Rio Clozapine Alert v2 23.5.24
- QPA 2024/20 Single Patient Use Medication Injectable Pen Devices (Update to previous QPA 2019-36) 22.05.24
- QPA 2023-59 v2 Care of Percutaneous Endosopic Gastrostomy (PEG) Tube 13.5.24
- QPA 2024-19 Utilisation of Lone Working Device
- QPA 2024-18 What to do if service users are unable to engage in decisions about care & treatment of physical conditions or unwilling to engage
- QPA 2024-17 Monitoring of patients prescribed lithium
- QPA 2024-16 Prescribing Trust owned Nebulisers from Community Equipment Stores
- QPA 2024-15 Choking Incidents: (i) Response to mild and severe obstruction (ii) Incident coding when submitting incident reports 28.3.24
- QPA 2024-14 Insulin Cartredges and Pen Devices 27.3.24
- QPA Allergy Status Confirmation and Recording 26.3.24
- QPA 2024-13 Correct Use of Different Sodium Chloride 0.9% Solution Formulations 08.03.24
- QPA 2023-44 Subcutaneous prescribing and administration of medication for pain relief in the last days of life v2 07.03.24
- QPA 2024-11 Safer Use of High Dose Antipsychotic Treatment 21.02.24
- QPA 2024-09 Safe Management and Storage of Controlled Drugs in Care Homes 15.02.24
- QPA_2024 Safe Use of Valproate Update 09.02.24
- QPA 2024-05 Oxygen Management within Walk in Centres_Urgent Care Treatment centres and Children’s Special Schools Community Care Division 29.01.24
- QPA 2024-04 Safe Medicines Administration v2 23.01.24
- QPA 2024-02 Escalation of Serious Controlled Drug Incidents 12.01.24
- QPA 2024- 07 Safe Use of Valproate Update- 09.01.24
- QPA 2023-64 v2 - Emergency Cabinets 02.01.24
- QPA 2023-65 Potential for inappropriate dosing of insulin when switching insulin degludec (Tresiba®) products 02.01.24
- QPA 2023-63 Safe Use of Valproate Update 13.12.23
- QPA 2023-59 Care of Percutaneous Endoscopic Gastrostomy (PEG) tube 20.11.23
- QPA 2023-58 Good Practice Prescribing of Antimicrobials 16.11.23
- QPA 2023-54 cardiac chest pain V5 13.11.23
- Revised QPA 2023 53 GlucoRx HCT External Quality Assurance BGM v2 01.11.23
- QPA 2023-50 Contraindications of use of inadine and all forms of cadexomer iodine and povidine-iodine 16.10.23
- Amended QPA 2023-43 Security of Controlled Drugs Keys v.2 08.09.23
- Rowlands Pharmacy Temporary Closure Hollins Park Pharmacy- 07.08.23
- QPA 2023-42 Prescribing on paper for wards with ePMA 2023 v1.3 14.08.23
- QPA 2023-40 Potent Synthetic Opioids V2 07.08.23
- QPA 2023-39 New Trust Wide MMP24 Safe Use of Clozapine Procedure V3 07.08.23
- Temperature Excursions Poster QPA 2023- 38a
- QPA 2023- 38 Dealing with Temperature Excursions- 28.07.23
- QPA 2023-36 Quetiapine Modified Release (MR)– Good practice prescribing principles 28.07.23
- Medicine Related Policy Procedure Update- 07.07.23
- Amended QPA 2023-32 Aripiprazole and impulsive behaviour 04.07.23
- QPA 2023-30 Melatonin Good Practice Prescribing Principles- 12.06.23
- QPA 2023-23- Amended Urgent Class 1 Recall of Emerade Auto-injector V2- 12.06.23
- QPA 2023- 31 GlucoRX HCT External Quality Assurance- 12.06.23
- QPA 2023- 27 Internal Transfer of Care; Inpatient Medication Records & Clinical Notes- 25.05.23
- QPA 2023- 24 Good Practice Prescribing of Antimicrobials- 15.05.23
- QPA 2023- 23 Urgent Class 1 Recall of Emerade Auto-injector- 11.05.23
- QPA 2023-22 Administration of antipsychotic depot injections in the acute hospital setting- 05.05.23
- QPA 2023-17 Raising awareness of sodium nitrite as a suicide agent - 05.04.23
- QPA 2023-16 Patient Identification- 13.03.23
- QPA 2023-15 Clonazepam added to restricted drug list - 08.03.23
- QPA 2023-13 Swich to a new formulation of paliperidone palmitate- 17.01.23
- QPA 2023-6 Inadvertent Oral Administration of Potassium Permanganate- 17.1.23
- QPA 2023- 1 Safe prescribing of medication, ensuring accuracy of medication records- 03.01.23
- QPA 2022- 82 Valproate prescribing for girls and women of childbearing potential-13.12.22
- QPA 2022-81 BNF access – a requirement for all staff working with medicines- 12.12.22
- QPA 2022-79 prescribing and administration of regular and when required medication- 18.11.22
- QPA 2022-77 Raising awareness of Neuroleptic Malignant Syndrome 003- 18.11.22
- QPA 2022-74 Recording Allergy Status on EPMA -16.11.22
- QPA 2022-73 Important update Rapid tranquilisation Policy and Procedures- 7.11.22
- QPA 2022-72 Sickle Cell Disease: Raising awareness of the disorder, key signs and symptoms and reccomended management of acute painful sickle cell crisis- 4.11.22
QPA 2022-71 Prescribing of 'when required' (PRN) medication- 4.11.22
-
QPA 2022-60 Good Practice Prescribing of Antimicrobials and Trust Perfect Care Goal- 02.09.22
- QPA 2022-58 Watch Out for Look-alikes & Sound- alike Medicines- 10.08.22
- QPA 2022-55 Reminder of staff responsibilities when issuing medication against a Patient Group Direction (PGD) (2)- 04.08.22
- QPA 2022-56 Reminder of the increased risk of suicidal ideation- 03.08.22
- QPA 2022-52 Pregabalin (Lyrica) findings of safety study on risks during pregnancy v.2- 27.07.22
- QPA 2022-51 NovoRapid Insulin 100units in 1ml and Saxenda liraglutide 6mg in 1ml Pre-filled Pen- 22.07.22
- QPA 2022-49 Prescribing ‘Dummy Drugs’ on the Electronic Prescribing Medicines Administration System (EPMA)- 22.07.22
- QPA 2022-44 Reminder of staff responsibilities relating to Controlled Drug activities (002)- 05.07.22
- QPA 2022-39 Safe Temperature Storage Conditions for Medication and Dressings- 23.06.22
- QPA 2022-36 Safe Prescribing of Oral Paracetamol in Patients Aged 16 Years and Over- 30.05.22
- QPA 2022-34 Alcohol Detox POMH Audit Findings- 27.05.22
- QPA 2022-35 Clozapine toxicity associated with change in smoking status- 27.05.22
- QPA 2022-31 Reminder of Under-Recognised Risk of Severe Toxicity from Propranolol Overdose- 22.05.22
- QPA 2022-24 Standards. compliance scores. key points identified inMid Mersey POMH national audit_Clozapine- 27.04.22
- QPA 2022-15 New perinatal guidelines on physical health monitoring with psychotropic medication-18.03.22
- QPA 2022-14 Clozapine_ Reminder of potentially fatal risk of intestinal obstruction faecal impaction and paralytic ileus- 15.03.22
- QPA 2022-03 Use of combinations of depots or long-acting antipsychotics is not recommended v.2- 20.01.22
- MEMO Venlafaxine formulary change August 2025 - 08.08.25
- Update & End to the shortage of Olanzapine LAI - 08.08.25
- MEMO Cost-effective prescribing 16.07.25
- Shortage alert for Bumetanide Actions required for staff by 11.07.25 - 09.07.25
- Memo - Interaction between Fluvoxamine & Melatonin 09.07.25
- Shortage alert - Venlafaxine 37.5mg Modified-Release Tablets 03.07.25
- Shortage alert - Galantamine 8mg, 16mg and 24mg modified release capsules 28.05.25
- Shortage alert - Hyoscine hydrobromide (Scopoderm) 1.5mg patches 16.05.25
- Memo - Valproate Prescribing 31.10.23